


## Uridine-<sup>13</sup>C

<b>Cat. No.:</b>	HY-B1449S1		
<b>CAS No.:</b>	201996-62-5		
<b>Molecular Formula:</b>	C <sub>8</sub> <sup>13</sup> CH <sub>12</sub> N <sub>2</sub> O <sub>6</sub>		
<b>Molecular Weight:</b>	245.19		
<b>Target:</b>	Endogenous Metabolite; Nucleoside Antimetabolite/Analog		
<b>Pathway:</b>	Metabolic Enzyme/Protease; Cell Cycle/DNA Damage		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (203.92 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	4.0785 mL	20.3923 mL	40.7847 mL
5 mM	0.8157 mL	4.0785 mL	8.1569 mL
10 mM	0.4078 mL	2.0392 mL	4.0785 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Uridine-<sup>13</sup>C is the <sup>13</sup>C labeled Uridine[1].

#### In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA